Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Giant Biogene Holding CoHKSE:02367 +1.24%85 FCF Margin % is 42.79% as of Dec. 2025, which is 14% above its 10-year median of 37.44. GuruFocus rates HKSE:02367 with a GF Score™ of 85/100 and a GF Value™ of HK$68.03 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 2,044 Consumer Packaged Goods companies, Giant Biogene Holding Co ranks better than 97.26% on this metric.
The historical rank and industry rank for Giant Biogene Holding Co's FCF Margin % or its related term are showing as below:
HKSE:02367'
s FCF Margin % Range Over the Past 10 Years
Min: 24.5 Med: 37.44 Max: 63.65
Current: 27.92
During the past 7 years, the highest FCF Margin % of Giant Biogene Holding Co was 63.65%. The lowest was 24.50%. And the median was 37.44%.
HKSE:02367's FCF Margin % is ranked better than 97.26% of 2044
companies
in the Consumer Packaged Goods industry
Industry Median: 1.655
vs HKSE:02367: 27.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Giant Biogene Holding Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Giant Biogene Holding Co FCF Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Giant Biogene Holding Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co (HKSE:02367) has a FCF Margin % of 42.79% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Giant Biogene Holding Co and its competitors. This is 14% above median its historical median of 37.44. Over the past decade, Giant Biogene Holding Co's FCF Margin % has ranged from 24.50 to 63.65. According to the industry distribution chart, Giant Biogene Holding Co ranks #56 out of 2044 companies in the Consumer Packaged Goods industry, placing it in the top 2.7%.
Is Giant Biogene Holding Co's FCF Margin % too high?
Giant Biogene Holding Co's current FCF Margin % of 42.79% is 14% above median its 10-year median of 37.44. Over the past 10 years, this metric has ranged from a low of 24.50 to a high of 63.65. The Consumer Packaged Goods industry median FCF Margin % is 1.66. Giant Biogene Holding Co's value of 42.79% is 2485.5% above this industry median. Based on the distribution chart, Giant Biogene Holding Co ranks #56 out of 2044 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Giant Biogene Holding Co has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Giant Biogene Holding Co's FCF Margin % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Giant Biogene Holding Co ranks #56 out of 2044 companies for FCF Margin %. This places Giant Biogene Holding Co in the top 3% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 1.66. Giant Biogene Holding Co's value of 42.79% is 2485.5% above this benchmark. Historically, Giant Biogene Holding Co's own FCF Margin % has ranged from 24.50 to 63.65 over the past decade. While the company's 10-year median is 37.44 vs. the industry median of 1.66, Giant Biogene Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Consumer Packaged Goods company?
The median FCF Margin % among Consumer Packaged Goods companies is 1.66, based on 2,044 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Giant Biogene Holding Co's current FCF Margin % of 42.79% is 2485.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Giant Biogene Holding Co and its competitors. For the Consumer Packaged Goods industry, the median FCF Margin % is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Giant Biogene Holding Co's current FCF Margin % is 42.79%, which is 14% above median its own 10-year median of 37.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Giant Biogene Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Giant Biogene Holding Co (HKSE:02367) is currently considered Possible Value Trap. The stock's GF Value™ is HK$68.03, compared to a current price of HK$24.46 — trading 64% below its estimated fair value. The current FCF Margin % is 42.79%, which is 14% above median its 10-year median of 37.44 and 2485.5% above the Consumer Packaged Goods industry median of 1.66. Giant Biogene Holding Co's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Giant Biogene Holding Co (HKSE:02367), the current FCF Margin % is 42.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Giant Biogene Holding Co (HKSE:02367) Overvalued in 2026?
Based on GuruFocus' analysis, Giant Biogene Holding Co stock appears to be undervalued.
The current stock price of HK$24.46 is trading 64% below its estimated GF Value™ of HK$68.03.
GuruFocus considers Giant Biogene Holding Co to be Possible Value Trap.
Key valuation signals for HKSE:02367:
FCF Margin %: 42.79% (14% above median its 10-year median of 37.44)
GF Value™: HK$68.03 vs. price of HK$24.46 (64% below fair value)
Industry Position: 2485.5% above the Consumer Packaged Goods median (#56 of 2044)
No single metric tells the full story. See the HKSE:02367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Giant Biogene Holding Co Ltd designs, develops, and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenoside technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop & manufacture multiple types of recombinant collagen & rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty & health properties such as skin repair, anti-aging, whitening, moisturizing, & immunity improvement, with a broad range of applications in the beauty & health sectors. The group is organised into a single business unit that mainly includes the research, development, manufacture, & sale of bioactive material-based beauty & health products.
85GF Score
Get the complete analysis for HKSE:02367
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02367 has been successfully added to your 
